A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)

© The Author 2016.Background: Phosphatidylinositol 3-kinase (PI3K) pathway activation in preclinical models of breast cancer is associated with tumor growth and resistance to anticancer therapies, including paclitaxel. Effects of the pan-Class I PI3K inhibitor buparlisib (BKM120) appear synergistic...

Full description

Bibliographic Details
Main Authors: Martín, M., Chan, Arlene, Dirix, L., O'Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M., Krivorotko, P., Batista López, N., Campone, M., Ruiz Borrego, M., Khan, Q., Beck, J., Ramos Vázquez, M., Urban, P., Goteti, S., Di Tomaso, E., Massacesi, C., Delaloge, S.
Format: Journal Article
Published: Oxford University Press 2017
Online Access:http://hdl.handle.net/20.500.11937/57649

Similar Items

Similar Items